Aphios Pharma (2)

Aphios Pharma is developing cannabis-based therapeutics for cancer pain, opioid use disorder and MS

Claim My Business
Technology, Social Impact, Community & Lifestyle, Sports & Fitness
Min Investment
Woburn, MA
Offering Date
June 18, 2021
Expected Close Date
January 31, 2019
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

Aphios is developing enabling technology platforms designed to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic drug safety. Using these enabling technology platforms, Aphios and its collaborators are developing enhanced therapeutics for health maintenance, disease prevention and the treatment of certain cancers, infectious diseases and Central Nervous System (CNS) disorders.


Key Deal Facts

Developing cannabis therapeutics as alternatives to synthetic drugs for highly unmet medical needs
Addressing a $4B market for cancer pain, $5B for opioid use disorder and $40B for Multiple Sclerosis
$44 million spent to date on developing enabling drug manufacturing and drug delivery technologies
$7.9M peer-reviewed grants from National Cancer Institute, National Institute on Drug Abuse and NCCIH, NIH
Supercritical fluid facility for manufacturing 1,000 kg pharma-grade cannabinoids per yr under cGMP
Fully-equipped Schedule I BSL-2 labs and cGMP suites for formulation and nanoencapsulation of cannabinoids
Our proprietary manufacturing and nanoencapsulation technologies are protected by 16 issued and 4 provisional patents
We are dedicated to sustainability, environmental responsibility and communal curtailment of climate change

Management Team / Advisory Board Bios

Trevor P. Castor, President & CEO
Dr. Castor has developed green enabling platforms for improving drug discovery and manufacturing, and nanotechnology drug delivery in an environmentally sustainable manner and nanoencapsulated cannabinoids for cancer pain, MS and opioid use disorder.

Dr. Val Livada, Busines Advisor
Dr. Val R. Livada is Founder and CEO of Weybridge Partners which is focused on successful technology commercialization. He was a Senior Lecturer (retired) on Corporate Entrepreneurship at the Sloan School of Management, MIT, Cambridge, MA.
Amount Raised : $95,661
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Research Reports

No reports have been submitted

Become a Reporter